Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2020, XXVI/2: 072-076 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2020, XXVI/2: 072-076

Title: Holmium laser enucleation of the prostate (HoLEP) as a new standard in surgery of benign prostatic hyperplasia 

Author: Zugaj P. 

More details

03-02-2020

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Holmium laser enucleation of the prostate (HoLEP) as a new standard in surgery of benign prostatic hyperplasia

Zugaj P.

Urological Department of st. Ann’s EMC Hospital in Piaseczno, Poland

International Review of Medical Practice, 2020; Vol. 26, No. 2, 072

Benign prostatic hyperplasia (BPH) is a chronic disease mostly affecting aging men. Such hyperplasia can cause physical obstruction of prostatic urethra and result in anatomic bladder outlet obstruction (BOO). Untreated BOO can lead to urinary retention. Surgical treatment is the most durable of all available methods. Historically, transurethral resection of the prostate or open simple prostatectomy have been the gold standard of surgical procedures. Nowadays holmium laser enucleation of the prostate (HoLEP), which appeared over 20 years ago, becoming more and more popular. It characterized by high efficiency and safety profile, surpass transurethral resection of the prostate (TURP) with durability and radicality. It is size independent an age independent procedure. HoLEP is a truly endoscopic alternative to open simple prostatectomy. Both, the European Urological Association (EAU) guidelines and American Urological Association (AUA) guidelines recommend HoLEP as the first choice procedure in case of larger adenoma and available treatment option in remaining BPH cases.

Key words: benign prostatic hyperplasia, holmium laser enucleation of the prostate